Leading-edge medical care through clinical research.
Getting care at AdventHealth Tampa, formerly Florida Hospital Tampa, means getting access to the latest heart care research studies, procedures, and technologies including access to heart treatment clinical trials that aren’t widely available elsewhere.
Active Research Trials
BIOFLOW-VII: Confirming that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device Exemption pivotal trial. Closed to enrollment. Lead: Juliet Bala
FROZEN: To establish the safety and effectiveness of the Boston Scientific Cardiac Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation. Lead: Cynthia Paysor
DIGESTIVE HEALTH TRIALS
ADMIRE-CD-II: Assess efficacy and safety of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease. Lead: Christopher Carr
Darvadstrocel-3003: Evaluate the long-term safety and efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects with Crohn’s Disease who have participated in ADMIRE-CD-II Study. Lead: Christopher Carr
G1T28: Utilization of trilaciclib to see the possible advantages in protecting the bone marrow and the immune system and improving chemotherapy antitumor efficacy in patients with metastatic triple negative breast cancer. Lead: Christopher Carr
GHPANC-1-001: Determine the maximum tolerated dose and evaluate the efficacy and safety of Antroquinonol in Combination with nab-paclitaxel and gemcitabine in first line Metastatic Pancreatic Cancer. Lead: Christopher Carr
PANOVA-3: Evaluate the effect of Tumor Treating Fields (TTFields, 150 kHz) as front line treatment of Locally Advanced Pancreatic Adenocarcinoma concomitant with gemcitabine and nab-paclitaxel. Lead: Christopher Carr
AMG-570/SLE: Determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies. Lead: Gretchen Pifer
B7931028: Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care. Lead: Dianne Morales
GSK-20190: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate. Lead: Judy Lara
GSK-20218: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors. Lead: Judy Lara
PA0010: A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL).